Is Pfizer Stock a Buy Now After Earnings?
While the COVID-19 pandemic is an increasingly distant memory for most investors, (NYSE: PFE) has struggled to move past the overhang of record vaccine sales and earnings in 2021 and 2022. The stock is down about 53% from its all-time high as the market wonders whether the pharmaceutical giant can find its next blockbuster drug.
The good news is that the company's latest results highlighted a growth rebound. Sales momentum from several recent product launches supports an improving outlook. Could Pfizer stock -- which currently has a compelling dividend yield of 5.8% -- make a good addition to your portfolio now? Here's what you need to know.
The challenge for Pfizer right now is to rebuild investor confidence with evidence that its long-term strategy is back on track. Fortunately, the company's second-quarter earnings (for the period ended June 30) have worked to move in that direction. Revenue growth turned positive, up 3% year over year, but an even more impressive 14% higher excluding the impact of the declining Comirnaty and Paxlovid COVID-19 programs.
Source Fool.com
Pfizer Inc. Aktie
Die Community neigt bei Pfizer Inc. zu Buy-Einschätzungen, mehr als zu Sell-Einschätzungen.
Das Community-Kursziel von 29 € für Pfizer Inc. deutet auf eine deutliche Steigerung um mehr als 20% gegenüber dem aktuellen Kurs von 22.83 € hin.
